- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
iShares Trust - iShares Neuroscience and Healthcare ETF(IBRN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IBRN
11/20/2026: IBRN (1-star) is currently NOT-A-BUY. Pass it for now.
The iShares Neuroscience and Healthcare ETF (IBRN) provides targeted global equity exposure to companies advancing research, therapeutics, and medical devices focused on brain health and neurological disorders. Its main strengths lie in its pure-play thematic mandate, global reach, and robust institutional backing by BlackRock. It serves primarily as a satellite growth allocation for investors looking to capture long-term demographic healthcare trends. Key risks include high sub-sector concentration, sensitivity to clinical trial outcomes, and lighter trading liquidity given its modest asset scale. The fund suits growth-focused investors willing to accept volatility in exchange for specialized exposure to medical innovation.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The fund targets innovative companies developing cutting-edge neurological therapies with significant long-term expansion potential. |
| Momentum investor | Strong fit while signal remains positive | Favorable clinical results or sector momentum can drive sharp rallies across specialized biotech holdings. |
| Value investor | Weak fit | Many underlying constituents are pre-revenue or clinical-stage firms trading on future potential rather than current earnings. |
| Dividend/Income investor | Weak fit | The fund emphasizes capital appreciation in innovation rather than cash distribution, offering minimal yield. |
| Low-risk investor | Weak fit | The thematic focus on specialized healthcare and clinical-stage equities introduces elevated volatility and clinical trial risk. |
Investor Profile
Ideal Investor Profile
Growth-oriented investors seeking targeted satellite exposure to specialized healthcare themes and long-term demographic trends.
Suitability
Best suited for long-term investors comfortable with thematic concentration risk and short-term volatility as part of a diversified portfolio.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | High | Thematic biotech and medical device stocks frequently experience sharp price fluctuations based on clinical updates. |
| Market risk | Medium / high | Broader macroeconomic downturns and shifting risk appetites directly impact growth-oriented healthcare valuations. |
| Concentration | High | The fund focuses tightly on a single niche sector (neuroscience), increasing vulnerability to regulatory or sector-specific shocks. |
| Tracking/expense | Low | The expense ratio of 0.47% is reasonable for a specialized global thematic product. |
| Liquidity | Medium / high | Lower average daily trading volumes can result in wider spreads during periods of market stress. |
| Business/sector quality | Medium | Constituents include a mix of established medical tech leaders and speculative clinical-stage biopharmas. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
Exhibits high historical volatility consistent with specialized biotech and medical innovation funds subject to binary clinical outcomes.
Market Risk
Vulnerable to sector-specific regulatory shifts, clinical trial setbacks, and broader macroeconomic cycles affecting growth assets.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Global Healthcare (Neuroscience Biopharma & MedTech) | 98 | Provides comprehensive thematic exposure to companies focusing on brain health, neurological disorders, and medical device innovations. |
| Cash/collateral | Cash and Cash Equivalents | 2 | Maintains minimal liquidity reserves for operational efficiency and daily creation/redemption activities. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit 39.56% | Avg. Invested days 76 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

